1. Adelaide Research & Scholarship

Browsing "Pharmacology" by Title

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 729 to 748 of 918 < previous   next >
PreviewIssue DateTitleAuthor(s)
2021Residential medication management reviews in Australian residential aged care facilitiesSluggett, J.K.; Bell, J.S.; Lang, C.; Corlis, M.; Whitehead, C.; Wesselingh, S.L.; Inacio, M.C.
2008Response to "No influence of ABCB1 haplotypes on methadone dosage requirement"Coller, J.; Barratt, D.; Somogyi, A.
2005Restoration of depressed prostanoid-induced ileal contraction in spontaneously hypertensive rats by dietary fish oilPatten, G.; Adams, M.; Dallimore, J.; Rogers, P.; Topping, D.; Abeywardena, M.
1995Restriction fragment length polymorphism of the apolipoprotein B gene and response to dietary fat and cholesterolAbbey, M.; Chen, G.Z.; Ross, R.; Noakes, M.; Belling, G.; Clifton, P.; Nestel, P.
2009Results of a phase IIa clinical trial of an anti-inflammatory molecule, chaperonin 10, in multiple sclerosisBroadley, S.; Vanags, D.; Williams, B.; Johnson, B.; Feeney, D.; Griffiths, L.; Shakib, S.; Brown, G.; Coulthard, A.; Mullins, P.; Kneebone, C.
2021Retention of opioid agonist treatment prescribers across New South Wales, Australia, 2001-2018: Implications for treatment systems and potential impact on client outcomesJones, N.R.; Nielsen, S.; Farrell, M.; Ali, R.; Gill, A.; Larney, S.; Degenhardt, L.
2006Reversal of morphine, methadone and heroin induced effects in mice by naloxone methiodideLewanowitsch, T.; Miller, J.; Irvine, R.
2022Review article: the future of microbiome-based therapeuticsGulliver, E.L.; Young, R.B.; Chonwerawong, M.; D'Adamo, G.L.; Thomason, T.; Widdop, J.T.; Rutten, E.L.; Rossetto Marcelino, V.; Bryant, R.V.; Costello, S.P.; O'Brien, C.L.; Hold, G.L.; Giles, E.M.; Forster, S.C.
2013Revisiting serotonin reuptake inhibitors and the therapeutic potential of "uptake-2" in psychiatric disordersDaws, L.; Koek, W.; Mitchell, N.
2009Risk assessment and communication tools for genotype associations with multifactorial phenotypes: The concept of "edge effect" and cultivating an ethical bridge between omics innovations and societyOzdemir, V.; Suarez-Kurtz, G.; Stenne, R.; Somogyi, A.; Someya, T.; Kayaalp, S.; Kolker, E.
2009Role of active metabolites in the use of opioidsColler, J.; Christrup, L.; Somogyi, A.
2000Role of cytochrome P450 3A in the metabolism of mefloquine in human and animal hepatocytesFontaine, Frank R.; de Sousa, G.; Burcham, Philip Cyril; Duchene, P.; Rahmani, R.
1999Role of endogenous adenosine in the expression of opiate withdrawal in rats.Salem, A.; Hope, W.
1997Role of G-T transversions in the mutagenicity of alkylperoxyl radicals: induction of alkali-labile sites in bacteriophage M13 mp19.Harkin, L.; Butler, L.; Burcham, P.
2008Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study GroupSchwab, M.; Zanger, U.; Marx, C.; Schaeffeler, E.; Klein, K.; Dippon, J.; Kerb, R.; Blievernicht, J.; Fischer, J.; Hofmann, U.; Bokemeyer, C.; Eichelbaum, M.
2006Role of MRP2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: Effect of cyclosporineWestley, I.; Brogan, L.; Morris, R.; Evans, A.; Sallustio, B.
2005Role of nitric oxide mechanisms in gastric emptying of, and the blood pressure and glycemic responses to, oral glucose in healthy older subjectsGentilcore, D.; Visvanathan, R.; Russo, A.; Chaikomin, R.; Stevens, J.; Wishart, J.; Tonkin, A.; Horowitz, M.; Jones, K.
2010Role of pharmacogenomics in pain therapy: Focus on opioidsSomogyi, A.; Hardy, J.
2009Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: A closer look at the agonist properties of bimatoprost and the prostamidesSmid, S.
2011Rosemary and cancer prevention: Preclinical perspectivesNgo, S.; Williams, D.; Head, R.
Showing results 729 to 748 of 918 < previous   next >